Tzield
FDA Delays Reviews for Eli Lilly, Sanofi, and Others in New Priority Voucher Program Due to Safety and Efficacy Concerns
FDA delays; Eli Lilly; Sanofi; voucher program; orforglipron; Tzield; safety concerns; efficacy issues
Actionable Insights Powered by AI
FDA delays; Eli Lilly; Sanofi; voucher program; orforglipron; Tzield; safety concerns; efficacy issues